BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 27760342)

  • 21. Immune response to Mycobacterium bovis bacille Calmette Guérin infection in major histocompatibility complex class I- and II-deficient knock-out mice: contribution of CD4 and CD8 T cells to acquired resistance.
    Ladel CH; Daugelat S; Kaufmann SH
    Eur J Immunol; 1995 Feb; 25(2):377-84. PubMed ID: 7875199
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Resting porcine T lymphocytes expressing class II major histocompatibility antigen.
    Saalmüller A; Weiland F; Reddehase MJ
    Immunobiology; 1991 Sep; 183(1-2):102-14. PubMed ID: 1834544
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Class I- and class II-reactive TCRs coexpressed on CD4+ T cells both trigger CD4/CD8-shared and CD4-unique functions.
    Asnagli H; Schmitt-Verhulst AM; Guimezanes A
    J Immunol; 1997 May; 158(10):4533-42. PubMed ID: 9144464
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Ovalbumin-specific, MHC class I-restricted, alpha beta-positive, Tc1 and Tc0 CD8+ T cell clones mediate the in vivo inhibition of rat IgE.
    MacAry PA; Holmes BJ; Kemeny DM
    J Immunol; 1998 Jan; 160(2):580-7. PubMed ID: 9551891
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Co-receptor-independent signal transduction in a mismatched CD8+ major histocompatibility complex class II-specific allogeneic cytotoxic T lymphocyte.
    Eshima K; Tachibana M; Suzuki H; Yamazaki S; Shinohara N
    Eur J Immunol; 1997 Jan; 27(1):55-61. PubMed ID: 9021998
    [TBL] [Abstract][Full Text] [Related]  

  • 26. T cell receptor transfection shows non-HLA-restricted recognition of nickel by CD8+ human T cells to be mediated by alphabeta T cell receptors.
    Moulon C; Choleva Y; Thierse HJ; Wild D; Weltzien HU
    J Invest Dermatol; 2003 Sep; 121(3):496-501. PubMed ID: 12925207
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Apparent MHC-independent stimulation of CD8+ T cells in vivo during latent murine gammaherpesvirus infection.
    Coppola MA; Flaño E; Nguyen P; Hardy CL; Cardin RD; Shastri N; Woodland DL; Blackman MA
    J Immunol; 1999 Aug; 163(3):1481-9. PubMed ID: 10415050
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Identification of SIV Nef CD8(+) T cell epitopes restricted by a MHC class I haplotype associated with lower viral loads in a macaque AIDS model.
    Nomura T; Yamamoto H; Takahashi N; Naruse TK; Kimura A; Matano T
    Biochem Biophys Res Commun; 2014 Jul; 450(2):942-7. PubMed ID: 24971540
    [TBL] [Abstract][Full Text] [Related]  

  • 29. T cell development in a major histocompatibility complex class II-deficient patient.
    van Eggermond MC; Rijkers GT; Kuis W; Zegers BJ; van den Elsen PJ
    Eur J Immunol; 1993 Oct; 23(10):2585-91. PubMed ID: 8405058
    [TBL] [Abstract][Full Text] [Related]  

  • 30. CD4 and CD8 accessory molecules function through interactions with major histocompatibility complex molecules which are not directly associated with the T cell receptor-antigen complex.
    Lustgarten J; Waks T; Eshhar Z
    Eur J Immunol; 1991 Oct; 21(10):2507-15. PubMed ID: 1915555
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Potent HIV-specific responses are enriched in a unique subset of CD8+ T cells that coexpresses CD4 on its surface.
    Zloza A; Schenkel JM; Tenorio AR; Martinson JA; Jeziorczak PM; Al-Harthi L
    Blood; 2009 Oct; 114(18):3841-53. PubMed ID: 19700667
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Incoming HIV virion-derived Gag Spacer Peptide 2 (p1) is a target of effective CD8
    Yang H; Llano A; Cedeño S; von Delft A; Corcuera A; Gillespie GM; Knox A; Leneghan DB; Frater J; Stöhr W; Fidler S; Mothe B; Mak J; Brander C; Ternette N; Dorrell L;
    Cell Rep; 2021 May; 35(6):109103. PubMed ID: 33979627
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Retroviral-mediated expression of an MHC class I-restricted T cell receptor in the CD8 T cell compartment of bone marrow-reconstituted mice.
    Pogulis RJ; Hansen MJ; Pease LR
    Hum Gene Ther; 1998 Oct; 9(15):2285-97. PubMed ID: 9794212
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Recognition of a shared human prostate cancer-associated antigen by nonclassical MHC-restricted CD8+ T cells.
    Housseau F; Bright RK; Simonis T; Nishimura MI; Topalian SL
    J Immunol; 1999 Dec; 163(11):6330-7. PubMed ID: 10570328
    [TBL] [Abstract][Full Text] [Related]  

  • 35. CD8+ TCR repertoire formation is guided primarily by the peptide component of the antigenic complex.
    Koning D; Costa AI; Hoof I; Miles JJ; Nanlohy NM; Ladell K; Matthews KK; Venturi V; Schellens IM; Borghans JA; Kesmir C; Price DA; van Baarle D
    J Immunol; 2013 Feb; 190(3):931-9. PubMed ID: 23267020
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Nef Is Dispensable for Resistance of Simian Immunodeficiency Virus-Infected Macrophages to CD8+ T Cell Killing.
    Rainho JN; Martins MA; Cunyat F; Watkins IT; Watkins DI; Stevenson M
    J Virol; 2015 Oct; 89(20):10625-36. PubMed ID: 26269172
    [TBL] [Abstract][Full Text] [Related]  

  • 37. CD4(+) T-cell dependence of primary CD8(+) T-cell response against vaccinia virus depends upon route of infection and viral dose.
    Hu Z; Molloy MJ; Usherwood EJ
    Cell Mol Immunol; 2016 Jan; 13(1):82-93. PubMed ID: 25544501
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Redirecting human CD4+ T lymphocytes to the MHC class I-restricted melanoma antigen MAGE-A1 by TCR alphabeta gene transfer requires CD8alpha.
    Willemsen R; Ronteltap C; Heuveling M; Debets R; Bolhuis R
    Gene Ther; 2005 Jan; 12(2):140-6. PubMed ID: 15496961
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Generation of stable CD4+ and CD8+ T cell lines from patients immunized with ras oncogene-derived peptides reflecting codon 12 mutations.
    Abrams SI; Khleif SN; Bergmann-Leitner ES; Kantor JA; Chung Y; Hamilton JM; Schlom J
    Cell Immunol; 1997 Dec; 182(2):137-51. PubMed ID: 9514698
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Frequency of class I HLA-restricted anti-HIV CD8+ T cells in individuals receiving highly active antiretroviral therapy (HAART).
    Gray CM; Lawrence J; Schapiro JM; Altman JD; Winters MA; Crompton M; Loi M; Kundu SK; Davis MM; Merigan TC
    J Immunol; 1999 Feb; 162(3):1780-8. PubMed ID: 9973442
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.